GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vascular Solutions Inc (NAS:VASC) » Definitions » Tax Expense

Vascular Solutions (Vascular Solutions) Tax Expense : $1.2 Mil (TTM As of Sep. 2016)


View and export this data going back to 2000. Start your Free Trial

What is Vascular Solutions Tax Expense?

Vascular Solutions's tax expense for the months ended in Sep. 2016 was $1.8 Mil. Its tax expense for the trailing twelve months (TTM) ended in Sep. 2016 was $1.2 Mil.


Vascular Solutions Tax Expense Historical Data

The historical data trend for Vascular Solutions's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vascular Solutions Tax Expense Chart

Vascular Solutions Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Tax Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.96 5.98 4.94 7.18 3.18

Vascular Solutions Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.44 -1.44 -0.62 1.48 1.82

Vascular Solutions Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vascular Solutions  (NAS:VASC) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


Vascular Solutions Tax Expense Related Terms

Thank you for viewing the detailed overview of Vascular Solutions's Tax Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


Vascular Solutions (Vascular Solutions) Business Description

Traded in Other Exchanges
N/A
Address
Vascular Solutions Inc was incorporated in the state of Minnesota in December 1996. It is a medical device company, creates new minimally invasive medical devices, and delivers these products and related services to physicians through its direct domestic sales force and its international distribution network. The Company's products and services are divided into three categories: Catheter products; Hemostat products and Vein products and services. Catheter products consist principally of catheters used in minimally invasive medical procedures for the diagnosis or treatment of vascular conditions, such as the GuideLiner catheter used to access discrete regions of the coronary anatomy and the Pronto extraction catheters used in treating acute myocardial infarction. Hemostat products consist principally of blood clotting products, such as the D-Stat Dry hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets. Vein products and services consist principally of the Vari-Lase endovenous laser, a laser console and procedure kit used for the treatment of varicose veins, and a reprocessing service for the ClosureFAST radiofrequency vein ablation catheter. The Company manufactures its products in its facilities located in the suburbs of Minneapolis, Minnesota and in the country of Ireland. The catheter manufacturing and packaging processes occur under a controlled clean room environment. It purchases components from various suppliers and rely on single sources for several parts of its products. It purchases its requirements for thrombin for use in manufacturing products sold in the U.S. under the Thrombin-JMI Supply Agreement with King. Its main competitors include: Medtronic, Boston Scientific, Covidien, Merit Medical, Marine Polymer Technologies, Cook Medical, Spectranetics, AngioDynamics and Terumo. The Company's products and services are regulated in the United States as medical devices by the FDA under the Federal Food, Drug and Cosmetic Act.
Executives
John L Erb director C/O VASCULAR SOLUTIONS, INC., 6464 SYCAMORE COURT N., MINNEAPOLIS, MN 55369
Richard Nigon director CEDAR POINT CAPITAL, 150 SOUTH 5TH STREET, MINNEAPOLIS MN 55402
Richard W Kramp director 174 STONEBRIDGE ROAD, ST. PAUL MN 55118
Stephens Group Inc 10 percent owner 111 CENTER ST, STE 2300, LITTLE ROCK AR 72201
Paulson J Robert Jr director
Gregg S Sutton officer: VP R&D 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Michael Nagel officer: VP of Sales C/O VASCULAR SOLUTIONS INC, 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Steve Patterson 10 percent owner 111 CENTER STREET STE 2300, LITTLE ROCK AR 72201

Vascular Solutions (Vascular Solutions) Headlines

From GuruFocus

Vascular Solutions Inc. (VASC) CEO Howard Root sells 25,000 Shares

By GuruFocus Research GuruFocus Editor 11-04-2010

Mairs & Power Comments on Vascular Solutions

By Holly LaFon Holly LaFon 12-01-2015

Mario Gabelli Comments on Vascular Solutions

By Holly LaFon Holly LaFon 01-31-2017